Compare DexCom, Inc. (DXCM) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M). The key difference: DexCom, Inc. is far larger — about 54.4× abrdn Physical Palladium Shares ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| DXCM | PALL | |
|---|---|---|
Market Cap | $31.86B | $586.03M |
Volume | 3,607,070 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $92.34 | $37.18 |
52-Week Low | $54.84 | $20.30 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
PALL trades at $20.49, up 0.94% today, but technical indicators signal a bearish trend with moving averages unanimously negative. Recent news highlights palladium's underperformance versus other precious metals, with some analysts viewing current price weakness as a buying opportunity due to supply risks and industrial demand potential. Financial ratios are unavailable, limiting fundamental assessment.
The outlook remains cautious; while oversold RSI levels suggest potential for a rebound, bearish momentum dominates. Key risks include commodity price volatility and reliance on industrial demand. Investors should weigh technical weakness against contrarian bullish arguments from recent analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
